| NCT ID | NCT06170541 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Johns Hopkins University |
| Condition | Coronary Heart Disease (CHD) |
| Study Type | INTERVENTIONAL |
| Enrollment | 140 participants |
| Start Date | 2021-04-05 |
| Primary Completion | 2026-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 140 participants in total. It began in 2021-04-05 with a primary completion date of 2026-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The utility of Ultra High-Resolution Computed Tomography (UHR-CT) compared to conventional CT in all-comers (i.e., a generally lower-risk population) remains uncertain but is an important area of study in order to justify wider spread implementation and use of this technology, particularly in light of reports of significantly higher radiation exposure with UHR-CT, as well as longer scan times. The availability of technology to reconstruct conventional resolution (CR) simulation images from the raw CT acquisition data acquired on the UHR-CT scanner offers a unique platform to study this question without subjecting individuals to two different scans. The primary objective of this study is to generate preliminary data in support of the hypothesis that noninvasive UHR-CT is superior to conventional resolution CT for identifying patients with obstructive CHD.
Eligibility Criteria
Inclusion Criteria: * Patients aged 21-85 years * Clinical history suggestive of CHD who are referred by their primary cardiologist for further evaluation via Computed tomography angiography (CTA) will be asked to participate. * Women of child bearing potential must demonstrate a negative pregnancy test within 24 hours of the study CTA. * Ability to understand and willingness to sign the Informed Consent Form. Exclusion Criteria: * Known allergy to iodinated contrast media. * History of multiple myeloma or previous organ transplantation * Elevated serum creatinine (\> 1.5mg/dl) OR calculated creatinine clearance of \< 60 ml/min (using the Cockcroft-Gault formula * Atrial fibrillation or uncontrolled tachyarrhythmia, or advanced atrioventricular block (second or third degree heart block) * Evidence of severe symptomatic heart failure (NYHA Class III or IV); * Known or suspected moderate or severe aortic stenosis * History of prior percutaneous coronary intervention (PCI) in one or more vessel or history of coronary arterial bypass grafting (CABG) * Suspected acute coronary syndrome * Presence of any other history or condition that the investigator feels would be problematic
Contact & Investigator
Joao Lima, Professor
PRINCIPAL INVESTIGATOR
MD
Frequently Asked Questions
Who can join the NCT06170541 clinical trial?
This trial is open to participants of all sexes, aged 21 Years or older, up to 85 Years, studying Coronary Heart Disease (CHD). Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06170541 currently recruiting?
Yes, NCT06170541 is actively recruiting participants. Contact the research team at jlima@jhmi.edu for enrollment information.
Where is the NCT06170541 trial being conducted?
This trial is being conducted at Baltimore, United States.
Who is sponsoring the NCT06170541 clinical trial?
NCT06170541 is sponsored by Johns Hopkins University. The principal investigator is Joao Lima, Professor at MD. The trial plans to enroll 140 participants.